Table 1.

Details of vaccines and vaccinations discussed in the manuscript

Study name	Vaccination regimen (schedule in weeks)	Vaccine inserts	Age range (Years)	Week of challenge initiation	Challenge virus used	Max No of challenges	Route & dose of challenge
M14 (n=10)	D-40L D-40L MM (0,8,16,24)	SIVmac239 Gag, Prt, RT and Env, CD40L with DNA	3 to 6	48	SIVmac251	8	Intra Rectal, 6.47×10^2 TCID50
P165 (n=33)	DDMM or D-GM D-GM MM (0,8,16,32)	SIVmac239 Gag, Prt, RT and Env; and GM-CSF with DNA in some animals	3 to 17	57	SIVsmE660-ABL (SIVsmE660 Hirsch 2000)	12	Intra Rectal, 4.12×10^2 TCID50
M15 (17)	DDMM or D-GM D-GM MM (0,8,16,24)	SIVmac239 Gag, Prt, RT and Env; and GM-CSF with DNA in some animals	3 to 19	48	SIVsmE660-ABL (SIVsmE660 Hirsch 2000)	12	Intra Vaginal, 10.2×10^3 TCID50
M19 (15)	DDMMM (0,8,16,24,38)	SIVmac239 Gag, Prt, RT and HIV 1086c Env	4 to 15	58	SHIV1157 ipd3N4	8	Intra Vaginal, 4.5×10^5 TCID50

D, DNA (3mg/dose, intramuscular); D-GM, DNA co-expressing macaque GM-CSF (3mg/dose, intramuscular); M, MVA (1×108 pfu/dose, intramuscular).